Last reviewed · How we verify
Tumor Infiltrating Lymphocyte
At a glance
| Generic name | Tumor Infiltrating Lymphocyte |
|---|---|
| Sponsor | Shanghai Juncell Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (PHASE2)
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
- TILs Therapy for Multiple Primary Early-Stage NSCLC (EARLY_PHASE1)
- Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin (NA)
- Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (PHASE2)
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tumor Infiltrating Lymphocyte CI brief — competitive landscape report
- Tumor Infiltrating Lymphocyte updates RSS · CI watch RSS
- Shanghai Juncell Therapeutics portfolio CI